Search
for
Sort by
Research 121–150 of 1000+
- Letters: CD4+ Lymphocytopenia in Systemic Lupus Erythematosus
- Kaposi varicelliform eruption
- Psychotropic Medications and the Skin
- Mucocutaneous Manifestations in HIV-Infected Patients and Their Relationship to CD4 Lymphocyte Counts
- Alopecia as a systemic disease
- A Review of the Most Common Dermatologic Conditions and their Debilitating Psychosocial Impacts
- Dermatological problems in the football player
- Pruritic urticarial papules and plaques of pregnancy
- A rare complication of follicular hair unit extraction: Kaposi’s varicelliform eruption
- Isomorphic and isotopic phenomenon occurring simultaneously in a case of granuloma annulare
- Cutaneous Adverse Drug Reactions (CADRs) to COVID19 vaccines: A case series
- Diagnosis of stress-associated dermatologic conditions in New York City safety-net hospitals during the COVID-19 pandemic
- Social isolation: main dermatosis and the impact of stress during the COVID-19 pandemic
- Male‐pattern baldness, common latent viruses, and microcompetition
- Effects of Wet Cupping on Blood Components Specially Skin-Related Parameters of Healthy Cases: A Case Control Metabonomic Study
- [Mycophenolate mofetil in induction and maintenance therapy for juvenile onset severe lupus nephritis].
- Seasonal Patterns and Trends in Dermatoses in Poland
- Updated Integrated Safety Analysis of Ritlecitinib Up to ~5 Years in Patients With Alopecia Areata From the ALLEGRO Clinical Trial Program
- Cutaneous manifestations associated with COVID-19 infection at a university hospital in eastern China
- Post Herpetic Itch Leading to Frictional Alopecia of Eyebrow and Scalp-A Hitherto Undescribed Phenomenon
- Incidence Rates of Infections, Malignancies, Thromboembolism, and Cardiovascular Events in an Alopecia Areata Cohort from a US Claims Database
- Viruses, Variants, and Vaccines: How COVID-19 Has Changed the Way We Look at Skin
- Cutaneous Manifestations of COVID-19
- Hair and Scalp Infections
- DENOUEMENT—CONTINUED FROM P. 661
- Janus Kinase (JAK) Inhibitors in Dermatology: An Update and Critical Review
- Updated Integrated Safety Analysis of Ritlecitinib Over 72 Months In Patients With Alopecia Areata From the ALLEGRO Clinical Trial Program
- Shared Spaces: Decoding Dual Dermatoses in a Single Dermatome
- Rates of Infections, Malignancies, Cardiovascular Outcomes, and Death in Individuals with Hospital-treated Alopecia Areata: A Registry-based Cohort Study in Denmark
- JAK kinase pathway inhibitor drugs in patients with moderate-to-severe alopecia: a real-world experience